Thymosin Alpha-1 (with Bacteriostatic Water)

Thymosin alpha-1 (Tα1) is a 28-residue N-terminally acetylated acidic peptide that was originally isolated from calf thymus by Allan Goldstein and colleagues in 1977 as one of the active components of "thymosin fraction 5" — a partially purified thymic extract that Goldstein had been studying since the 1960s for its effects on T-cell development and immune function. The isolation, sequence determination, and chemical synthesis of Tα1 in the late 1970s placed the peptide at the center of the broader "thymic peptides" research field that emerged in that era, and Tα1 went on to become the most clinically developed of the thymic peptides — approved as a medicine in over thirty countries (predominantly in Asia and Europe) for various immunological indications, though notably never approved by the FDA in the United States.

Despite its long research history and its substantial international clinical-development footprint, Tα1 remains an interesting and somewhat unusual peptide in the broader research-peptide landscape. The molecular mechanism — once an open question — has been substantially clarified over the past two decades through work characterizing Tα1's interaction with Toll-like receptor 2 and Toll-like receptor 9, and through characterization of effects on dendritic cell biology, on T-cell development, and on broader integration with innate and adaptive immunity. The endogenous biology of the peptide has been clarified through the recognition that Tα1 is generated by proteolytic processing of the precursor protein prothymosin alpha, with the processing pathway revealing connections to apoptosis biology that have been part of the modern reframing of the peptide's biology.

This page is an educational reference for readers who want a careful, plain-English explanation of what thymosin alpha-1 actually is, where it sits in the long history of thymic-peptide research, what the published research describes about its mechanisms and effects across the immunomodulatory landscape, and where it fits in the broader research-peptide ecosystem. It is not a medical guide, does not describe any therapy or immune-modulation protocol, and makes no claims about effects in people who acquire the compound for research purposes. Thymosin alpha-1 supplied as a research peptide is intended for laboratory and analytical work only.

Thymosin alpha-1 is a 28-residue linear acidic peptide with the sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn (with N-terminal acetylation as the only post-translational modification). The molecular formula is C129H215N33O55 (free acid form, with N-terminal acetylation), and the molecular weight is approximately 3108 daltons. The peptide is in the all-L-amino-acid configuration, has no disulfide bonds (no cysteines in the sequence), no glycosylation, and no other covalent modifications beyond the N-terminal acetylation.

The amino acid composition gives Tα1 a distinctively acidic character. The peptide contains eight glutamate and five aspartate residues — thirteen acidic side chains in a 28-residue peptide — partially offset by four lysines. The net charge at physiological pH is strongly negative (approximately -9), giving the peptide one of the most acidic isoelectric points among the well-characterized neuropeptides and immunopeptides. This strongly acidic character is one of the distinctive structural features of the peptide and has biophysical consequences for its interactions with various potential receptor and signaling partners.

The endogenous biological origin of Tα1 is from proteolytic processing of the precursor protein prothymosin alpha, encoded by the PTMA gene. Prothymosin alpha is a 109-residue acidic intrinsically disordered protein that is widely expressed across tissues (not exclusively in the thymus, despite the historical name) and that has been characterized for multiple intracellular functions including roles in chromatin biology, in apoptosis regulation, and in oxidative-stress responses. The proteolytic processing of prothymosin alpha to generate Tα1 — characterized in published research as occurring at least in part during apoptosis through caspase-mediated cleavage — generates the 28-residue Tα1 corresponding to residues 1-28 of prothymosin alpha. Both intracellular and extracellular processing pathways have been characterized in the published research literature.

The proposed mechanism of Tα1's immunomodulatory effects has been substantially clarified over the past two decades. The peptide has been characterized as a ligand for Toll-like receptor 2 (TLR2) and for Toll-like receptor 9 (TLR9), with the consequent downstream MyD88-dependent signaling driving effects on dendritic cell maturation, on cytokine production, on T-cell development and differentiation, and on broader immune effector function. The TLR mechanism distinguishes Tα1 from many of the older proposed mechanisms in the field (direct effects on thymic-stromal interactions, undefined receptor effects, etc.) and represents a substantial clarification of the peptide's molecular biology.

It is worth being specific about what Tα1 is not. It is not a thymic hormone in the classical endocrine sense — the regulation, expression pattern, and biology of prothymosin alpha and its processing products do not fit the classical hormone model. It is not the only "thymosin" — the original thymosin fraction 5 contained many distinct peptide and protein species (thymosin beta-4, thymosin beta-10, others), and the "thymosin" name is shared across structurally distinct peptide families with distinct biological functions. And although it is approved as a medicine in numerous international jurisdictions for various indications (Zadaxin and related trade names), it is not approved by the FDA in the United States; the research-peptide form is supplied for laboratory and analytical use only.

The history of thymosin alpha-1 begins with the broader thymic-extract research that was an active area of immunology in the 1960s and 1970s. The recognition that the thymus plays an essential role in T-cell development (work by Jacques Miller and others in the 1960s) raised the question of whether the thymus produced soluble factors that mediated some of its T-cell-developmental functions. Multiple research groups characterized various thymic extracts for biological activities on T-cell-precursor differentiation and on T-cell function in animal-model and in-vitro systems.

Allan Goldstein, working initially at Albert Einstein College of Medicine and later at George Washington University, was one of the principal investigators in this field. Goldstein and colleagues prepared a partially purified thymic extract — designated "thymosin fraction 5" — that had biological activity in T-cell-development and immune-function bioassays. Fraction 5 was characterized as a mixture of multiple peptide and protein species, and through the 1970s the Goldstein group worked to purify and identify the individual active components. The isolation and structural identification of thymosin alpha-1 was published in 1977, and the peptide became one of the most prominent identified components of the broader thymic-peptide field.

The 1980s saw the chemical synthesis of Tα1 and the beginning of its clinical-research development. The peptide was investigated in various clinical-research contexts including chronic viral hepatitis (particularly hepatitis B and hepatitis C), various oncology contexts, and immunocompromised-host contexts. The development was pursued primarily outside the United States, and the peptide was eventually approved as a medicine (typically marketed as Zadaxin) in over thirty countries — predominantly in Asia (China and various Southeast Asian countries) and in parts of Europe and South America. The peptide was not approved by the FDA in the United States, where multiple clinical trials in hepatitis C did not achieve the regulatory endpoints required for approval.

The mid-2000s saw the clarification of Tα1's molecular mechanism through work characterizing the peptide as a ligand for Toll-like receptor 2 (TLR2) and Toll-like receptor 9 (TLR9). Work by Luigina Romani's group in Perugia and collaborators (publishing principally from 2004-2010) characterized the TLR-mediated signaling, the consequent effects on dendritic cell maturation and on T-cell development (with effects on regulatory T cell, Th1, and Th17 differentiation depending on context), and the integration with broader innate-immune signaling. This mechanism clarification represented a major reframing of Tα1 biology and connected the peptide to the broader Toll-like-receptor immunology field that was rapidly developing in that era.

The 2010s and 2020s have seen continuing Tα1 research across multiple domains: continuing clinical-research development in the international jurisdictions where the peptide is approved as a medicine; continuing characterization of the TLR2/TLR9 mechanism and the downstream signaling; characterization of the connections to prothymosin alpha processing biology including the apoptosis-related processing pathways; characterization of effects in specific disease contexts including infectious-disease research (notably some COVID-19 research during 2020-2022), oncology research, and various immunocompromised-host research contexts; and continuing structure-activity exploration. The continuing research-peptide use of Tα1 in laboratory contexts reflects both its clinical-development history in numerous jurisdictions and its continuing interest as a tool for characterizing thymic-peptide biology.

The science of thymosin alpha-1 is organized around three connected areas: the molecular mechanism through TLR2 and TLR9 signaling, the downstream effects on dendritic cells and T-cell development, and the broader endogenous biology connecting Tα1 to its prothymosin alpha precursor and to the apoptosis-related processing pathway.

• 28-residue N-terminally acetylated acidic peptide; MW approximately 3108 Da; net charge approximately -9 at physiological pH.
• Originally isolated from calf thymus by Allan Goldstein in 1977 from thymosin fraction 5.
• Generated by proteolytic processing of the 109-residue precursor prothymosin alpha, including caspase-mediated apoptotic processing.
• Acts as a ligand for Toll-like receptor 2 (TLR2/TLR6) and Toll-like receptor 9 (TLR9), triggering MyD88-dependent signaling.
• Approved as a medicine (typically Zadaxin) in over thirty countries for various immunological indications; not approved by FDA in the US.

Structurally, thymosin alpha-1 is a linear 28-residue peptide with the sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn (with N-terminal acetylation as the only post-translational modification). The molecular formula is C129H215N33O55 with N-terminal acetylation, and the molecular weight is approximately 3108 daltons.

The amino acid composition is the most distinctive structural feature. Eight glutamate residues and five aspartate residues — thirteen acidic side chains in 28 residues — give the peptide a strongly acidic character. The four lysine residues provide some positive charge to partially offset, but the net charge at physiological pH is strongly negative (approximately -9), placing the isoelectric point well below physiological pH. This strongly acidic isoelectric point is shared with the parent prothymosin alpha protein and is one of the unusual features of the broader prothymosin/parathymosin family.

The peptide has no cysteines (no disulfide bonds), no aromatic residues (no tryptophan, tyrosine, or phenylalanine — which means minimal UV absorbance at the standard 280 nm wavelength and the need for alternative concentration-determination approaches such as quantitative amino acid analysis), and no other unusual residues beyond the N-terminal acetylation. The peptide is largely unstructured in aqueous solution at physiological ionic strength, consistent with the broader intrinsically-disordered character of the parent prothymosin alpha protein, and adopts secondary structure (some alpha-helical content) under conditions of reduced solvent polarity or in the presence of certain binding partners.

The molecular weight of approximately 3108 daltons places Tα1 in the small-to-medium peptide range — larger than the small peptides such as KPV but substantially smaller than insulin or other small proteins. The combined characteristics — all-L-amino-acid composition, no disulfide bonds, no unusual residues, strongly acidic character, intrinsically disordered conformation in aqueous solution — give the molecule the structural profile of an intrinsically disordered acidic peptide rather than a globular folded protein.

Thymosin alpha-1 is studied across laboratory contexts in immunology and infectious-disease and oncology research.

In TLR-signaling and innate-immunity research, Tα1 is used in characterization of the TLR2/TLR6 and TLR9 engagement, the downstream MyD88-dependent signaling, the NF-κB and MAPK pathway responses, and the integration with the broader pattern-recognition-receptor signaling landscape. The TLR-signaling applications include in-vitro studies using cells expressing the relevant TLRs, studies using TLR-knockout mouse models, and broader characterizations of how Tα1 fits into the pattern-recognition-receptor immunology field.

In dendritic-cell biology research, Tα1 is used in characterization of effects on dendritic cell maturation markers, on cytokine production, on antigen-presenting function, and on the integration with downstream T-cell responses. The dendritic-cell research applications include both myeloid and plasmacytoid dendritic cell contexts and integration with the broader dendritic-cell immunology field.

In T-cell development and differentiation research, Tα1 is used in characterization of effects on regulatory T cell biology, on Th1-versus-Th2-versus-Th17 differentiation balance, on T-cell effector function, and on broader integration with the adaptive-immune response landscape. The T-cell research applications connect the upstream Tα1-TLR-dendritic-cell effects to the downstream adaptive-immune outcomes that are the proximal substrate for many of the peptide's clinical-research applications.

In infectious-disease research, Tα1 is studied in various viral, fungal, and bacterial-infection models. The viral-hepatitis research context (hepatitis B and C) is the historical clinical-development context. Fungal-infection research (notably Aspergillus, where the Romani group's work has been extensive) has been a particularly active area. The 2020-2022 period saw a substantial burst of COVID-19-related Tα1 research and clinical investigation. Broader sepsis-research applications are also part of the contemporary research landscape.

In oncology research, Tα1 is used in characterization of effects on antitumor immunity in various tumor models including hepatocellular carcinoma (connecting to the hepatitis-C context), melanoma, and various other cancer types. The oncology research applications include both basic mechanism characterization and clinical-research investigation in the international jurisdictions where the peptide is approved as a medicine.

In broader prothymosin-alpha research, Tα1 is used as a tool for characterizing the biology of the parent prothymosin alpha protein, the processing pathways that generate the various proteolytic fragments, and the integration with the broader chromatin and apoptosis biology of the parent protein.

Across all of these contexts, the research applications are laboratory and analytical in nature. The research-peptide supply of Tα1 is intended for laboratory work only and does not include any clinical, therapeutic, or immune-treatment context.

Thymosin alpha-1 sits within the broader family of "thymosins" (peptides originally identified from thymic extracts but structurally diverse) and within the immunomodulatory-peptide landscape more generally.

Thymosin alpha-1 is a 28-residue N-terminally acetylated acidic peptide of approximately 3108 daltons, originally isolated from calf thymus by Allan Goldstein and colleagues in 1977 as one of the active components of the partially purified thymic extract designated 'thymosin fraction 5.' The peptide is generated endogenously by proteolytic processing of the 109-residue intrinsically disordered precursor protein prothymosin alpha, with characterized processing pathways including caspase-mediated apoptotic cleavage that releases Tα1 as a soluble extracellular mediator.

The molecular mechanism of Tα1's immunomodulatory effects has been substantially clarified over the past two decades through work characterizing the peptide as a ligand for Toll-like receptor 2 (TLR2/TLR6 heterodimer) and Toll-like receptor 9 (TLR9). The TLR engagement triggers MyD88-dependent signaling, NF-κB and MAPK pathway activation, and downstream effects on dendritic cell maturation, on T-cell development and differentiation balance (including effects on regulatory T cell, Th1, Th2, and Th17 biology in context-dependent fashion), and on broader integration with innate and adaptive immunity. This TLR mechanism has connected Tα1 to the broader pattern-recognition-receptor immunology landscape and represents a substantial clarification relative to the older proposed mechanisms in the field.

Tα1 has an unusual position in the broader research-peptide landscape because it is approved as a medicine (typically Zadaxin) in over thirty international jurisdictions — predominantly in Asia and parts of Europe and South America — for various immunological indications including chronic viral hepatitis, various oncology indications, and immunocompromised-host contexts. The peptide is notably not approved by the FDA in the United States, where the hepatitis C clinical trials did not achieve the regulatory endpoints required for approval. The international clinical-development footprint and the substantial published research literature make Tα1 one of the more extensively characterized peptides in the broader immunomodulatory-peptide landscape.

The research-peptide form is supplied for laboratory and analytical use only, independent of the medicine approvals in other jurisdictions, and educational discussion should remain within that framing rather than drift into therapeutic claims about humans.

For students, researchers, and curious readers approaching thymosin alpha-1 for the first time, the most accurate framing is of a thymic-derived immunomodulatory peptide with a substantial clinical-development history in numerous international jurisdictions, with a now-well-characterized TLR2/TLR9 mechanism that has integrated the peptide into the modern pattern-recognition-receptor immunology landscape, with continuing research interest in infectious-disease, oncology, and broader immunomodulation contexts, and with a place in the research-peptide ecosystem as both a historically important member of the thymic-peptide field and as a continuing tool for characterizing immunomodulatory biology.